Rating Scheme for Recommendations Strength of Recommendation Quality of Evidence for Recommendation
A: Strong recommendation for the statement.
B: Moderate recommendation for the statement.
C: Optional recommendation.
I: One or more randomized trials with clinical outcomes and/or validated laboratory endpoints.
II: One or more well designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes.
III: Expert opinion.
Abbreviations 3TC, lamivudine; ABC, abacavir; AIDs, acquired immunodeficiency syndrome; ART, antiretroviral therapy; ARV, antiretroviral; ATV, atazanavir; AZT, zidovudine; bid, twice daily; BUN, blood urea nitrogen; CCR5, chemokine receptor 5; CD4, cluster of differentiation 4; ClCr, creatinine clearance; CNS, central nervous system; ddI, didanosine; DLV, delavirdine; DRV, darunavir; d4T, stavudine; Dx, diagnosis; EC, enteric coated; EFV, efavirenz; EIA, enzyme immunoassay; ETR, etravirine; FPV, fosamprenavir; FTC, emtricitabine; HBV, hepatitis B virus; HIV, human immunodeficiency virus; HLA-B, human histocompatibility surface antigen encoded by the b locus; IDV, indinavir; IGRA, interferon-gamma release assay; INSTI, integrase strand transfer inhibitor; kg, kilogram; LPV, lopinavir; LPV/r, lopinavir/ritonavir; MDR, multidrug-resistant TB; mg, milligram; mL, milliliter; mm, millimeter; mo, month(s); MVC, maraviroc; NFV, nelfinavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; Pap, stained cells in a cervical smear; PI, protease inhibitor; PPI, proton pump inhibitor; pts, patients; q, every; /r, low dose ritonavir; RAL, raltegravir; RNA, ribonucleic acid; RPR, rapid plasma reagin; RPV, rilpivirine; RTV, ritonavir; SQV, saquinavir; STDs, sexually transmitted diseases; TB, tuberculosis; TDF, tenofovir; tid, three times daily; TPV, tipranavir; TST, tuberculin skin test; T-20, enfuvirtide; VDRL, Venereal Disease Research Laboratory slide test; XDR, extensively drug-resistant TB; ZDV, zidovudine
Source Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1–239. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 14, 2011; 1–167. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed October 18, 2011.
Disclaimer
This Guideline attempts to define principles of practice that should produce high-quality patient care. It focuses on the needs of primary care practice, but also is applicable to providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aſter consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool.
PRINTCODE
5740 Executive Drive Suite 218 Baltimore, MD 21228 TEL: 410-869-3332 • FAX: 410-744-2150 For additional copies: orders@GuidelineCentral.com Copyright © 2012 All rights reserved
28PRZ11012R1
